Navigation Links
Biotech Industry Veteran Joseph Bolen Joins Moderna Therapeutics to be President of Research and Development
Date:7/31/2013

CAMBRIDGE, Mass., July 31, 2013 /PRNewswire/ -- Moderna Therapeutics, the pioneering company developing messenger RNA therapeutics™, a revolutionary new treatment modality to enable the in vivo production of therapeutic proteins, announced today that Joseph Bolen, Ph.D., joined Moderna as its president of research and development (R&D).

Dr. Bolen, the chief scientific officer and global head of oncology research at Millennium: The Takeda Oncology Company has served in senior leadership positions at Millennium since 1999. As the Millennium CSO and global head of research, Dr. Bolen has a proven track record of leading a large and multi-faceted international R&D organization while fostering a culture of scientific innovation within a global commercial-stage company. He has more than 30 years of industry and research experience and has been at the forefront of cancer and immunology research since starting his career as a scientist at the National Institutes of Health (NIH).

"Messenger RNA therapeutics™ promises to vastly expand the number of diseases we can treat and usher in an entirely new era of drug discovery and development," said Stephane Bancel, president and founding CEO of Moderna. "To advance our internal programs in genetic rare diseases and oncology and support partners in many additional therapeutic areas, we are building an R&D organization that is second to none. Joe's deep scientific knowledge and strong vision will help us to create a culture and a structure that can move rapidly to turn scientific innovation into therapies that make a true difference for patients. I am very happy and honored to partner with such an accomplished and thoughtful scientific leader and drug hunter as Joe to build a very special company for patients and our team."

Dr. Bolen will oversee all aspects of R&D at Moderna, including dis
'/>"/>

SOURCE Moderna Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Biotechnology (BSMA) Conference For Supply Chain Professionals Returns To Foster City, October 8-9, 2013
2. Plant Biotechnology Companies Begin New Conversation about GMOs and How our Food is Grown
3. Nobel Laureate Dr. Oliver Smithies to Deliver Plenary Session at ISPE Biotechnology Symposium
4. Biotech Investment Group Launches Formex, LLC
5. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
6. TriMix for Travel Now Available at KRS Global Biotechnology
7. Chief Medical Officer Summit for Biotechs Goes West
8. PROLOR Biotech To Present New Data On Its Long-Acting Human Growth Hormone And Long-Acting Oxyntomodulin At ENDO 2013
9. Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex Biotechnology Index Fund
10. MedReps.com Report Shows Biotech Workers Earn the Most in Medical Sales
11. Biotechnology Master’s at UMBC Shady Grove - Virtual Info Session to Be Held on June 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)...  PDL BioPharma, Inc. (PDL, or the Company) (NASDAQ: ... release its second quarter 2015 financial results for the ... 2015, after market close. PDL,s management will host a ... Eastern Time to discuss the financial results.  A slide ... the webcast link on the PDL website. ...
(Date:7/28/2015)... , July 21, 2015 Research ... addition of the "Biomedical Refrigerators and Freezers ... Trends and Forecast 2014 - 2022" report ... biomedical refrigerators and freezers market has been segmented ... centers, blood banks, and others. The others segment ...
(Date:7/28/2015)... , July 28, 2015  Moerae Matrix Inc. ... 1 clinical trial with MMI-0100, a first-in-class inhibitor ... developed for pulmonary disorders characterized by inflammation and ... United Kingdom , is a double-blind, two-way ... the safety and tolerability of MMI-0100 when given ...
(Date:7/28/2015)... Israel , July 28, 2015 ... a regenerative medicine company utilizing its proprietary plant-based ... that Shomrat Shurtz has been appointed Senior Director ...      (Photo: http://photos.prnewswire.com/prnh/20150728/246955 ) , ... of experience in marketing, regulatory and business strategy. ...
Breaking Biology Technology:PDL BioPharma to Announce Second Quarter 2015 Financial Results on August 5, 2015 2Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 2Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2CollPlant Names Shomrat Shurtz Senior Director of Business Development 2
... Firms Recommend Pharmion ... merger with Celgene Special Meeting ... Corp. Urges All Shareholders to Vote FOR the Proposed Merger, ... ) today announced that Institutional Shareholder Services,(ISS) has recommended that ...
... and Vaccine Immunology, ANN ARBOR, Mich., Feb. 26 ... have demonstrated their nasally,delivered vaccinia vaccine can protect animals ... without the safety risks of,current vaccines for smallpox. Vaccinia ... it., The new vaccine confers a high level ...
... Switzerland, February 26 Arpida Ltd.,(SWX: ARPN) today reported ... for intravenous iclaprim in its first indication,complicated Skin and ... few weeks., Arpida has agreed with the U.S. ... a rolling process. Using a ,rolling NDA, allows modules,within ...
Cached Biology Technology:ISS Recommends Pharmion Shareholders Vote for Merger With Celgene 2ISS Recommends Pharmion Shareholders Vote for Merger With Celgene 3Nasal Vaccine for Smallpox Confers High Levels of Immunity Without Safety Risks 2Nasal Vaccine for Smallpox Confers High Levels of Immunity Without Safety Risks 3Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim 2Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim 3
(Date:7/13/2015)... 13, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, ... 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND ... and secure method to make payments.  With this ... introduced with its groundbreaking voice-direct payment patent application, ...
(Date:7/9/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/98rrmr/biometrics_for ... "Biometrics for Banking; Market & Technology Analysis, Adoption ... offering. The adoption for banking purposes ... the forecast is that by 2020 it will ... in delivering biometric systems to the banking industry. ...
(Date:7/9/2015)... July 9, 2015  Synaptics Inc. (NASDAQ: ... human interface solutions, today announced a new ... fully hardware encapsulated fingerprint sensor and matching ... is literally off the grid, isolating fingerprint ... within the fingerprint sensor to provide ultimate ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
... published online this week in the Proceedings of the ... a novel hepatitis C-like virus in dogs. The identification ... how hepatitis C in humans may have evolved and provides ... how it causes disease. The research was conducted ...
... on May 14, Nobel Prize laureate Prof. Sir Harold ... Michael S. Waterman of the University of Southern California ... Doctorate degrees awarded at this year,s TAU Board of ... previous honorees that includes heads of state, world-renowned artists, ...
... University of Louisville researchers have replicated the inflammatory ... from mild to severe diabetic nephropathy, using a mouse ... article published today in the journal Experimental Nephrology ... failure. "In 2004 we published an article that ...
Cached Biology News:Discovery of canine hepatitis C virus opens up new doors for research on deadly human pathogen 2Discovery of canine hepatitis C virus opens up new doors for research on deadly human pathogen 3Tel Aviv University confers its highest honor on 8 distinguished individuals 2UofL researchers replicate human kidney gene changes in mouse model 2
KNP-1 (HES1) Purified Anti-Mouse, Anti-Rat, Anti-Human, Anti-Dog, Anti-Chicken clone 35, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
... E978 GenBank Accession ... Immunogen : NY-ESO-1 full-length ... ascites with 0.05% sodium ... evaluated by immunoblot on ...
NATIVE RAT OSTEOCALCIN...
Form: Ready to use Applications: Immunohistology-frozen, Immunohistology-paraffin, Western Blot, ELISA...
Biology Products: